Goodwin Procter advised Disc Medicine, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriter. Disc Medicine, Inc. (Nasdaq: IRON) (“Disc”) announced...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Georgiamune Inc. on the transaction. Georgiamune Inc. announced the clearance of its Investigational New Drug application by the US Food...
You must be a Standard 1 Year member to access this content.
WilmerHale represented Volastra Therapeutics on the deal. Volastra Therapeutics, a clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), closed its $60 million Series...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer...
You must be a Standard 1 Year member to access this content.
